SG
SEEL

StoneX Group’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

StoneX Group’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4
Closed -$2.58K – 747
2023
Q3 		$2.58K Buy
4
+1
+33% +$4.29K ﹤0.01% 619
2023
Q2 		$14.3K Hold
3
– – ﹤0.01% 570
2023
Q1 		$6.91K Hold
3
– – ﹤0.01% 615
2022
Q4 		$6.79K Buy
+3
New +$10.5K ﹤0.01% 580
2022
Q3 		– Sell
-4
Closed -$10.2K – 763
2022
Q2 		$10.2K Buy
+4
New +$10.4K ﹤0.01% 672

Other funds holding SEEL

Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $9.37B AUM 23.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

StoneX Group's SEEL Position: Q4 2023 in Review

StoneX Group sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2023, closing a stake of 4 shares — an estimated $2.58K sold.

StoneX Group first reported a position in SEEL in Q2 2022 and held it in 5 quarters. The position peaked at $14.3K in Q2 2023. 32 funds tracked by Wall St. Rank hold SEEL as of Q4 2023.

  • StoneX Group reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • StoneX Group sold 4 Seelos Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $2.58K.
  • StoneX Group first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2022 and held it in 5 quarters.
  • StoneX Group's Seelos Therapeutics, Inc. Common Stock position peaked at $14.3K in Q2 2023.
  • 32 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2023.

Based on StoneX Group's 13F filing for Q4 2023, filed 12 Feb 2024.